Enosis Therapeutics — an Australian psychedelic start-up — has been pioneering a new variety of psychedelic therapy involving modern technology with the help of a German healthcare company.
On Monday, the company announced that it had entered into a partnership with OVID Clinics to help implement what it believes is the world’s first in-clinic application of psychedelic therapy in conjunction with virtual reality.
OVID Clinics is a Berlin-based healthcare services provider that will now be giving patients the option to experience psychedelics in combination with the so-called science-backed virtual technology protocols from Enosis.
Milosz Marganski, VR Lead at Enosis. Photo via Enosis Therapeutics.
Read more: Spirit Plant Medicine Conference returns at UBC to discuss psychedelics and consciousness
Read more: Algernon partners with Yale University for phase II DMT study
The news follows positive results obtained by Enosis through research conducted this June in partnership with Swinburne University of Technology in Australia. High levels of “acceptance and satisfaction” were reported by participants who had experienced a combination of psychedelic therapy and VR during the course of the study, which has inspired Enosis to begin offering its unorthodox variety of therapy at OVID Clinics.
“Enhancing patient accessibility to our VR experiences remains our top priority and we are excited to bring this novel treatment to patients in need. Together with the OVID team, our focus is to achieve positive patient outcomes and longer-lasting therapeutic benefits for patients battling mental health illnesses,” said Agnieszka D. Sekula, Co-Founder of Enosis Therapeutics.
Enosis says that the partnership with OVID proves that VR is an efficacious technology for improving mental health and that the technology’s protocols and capabilities are steadily gaining momentum in psychedelic studies and clinical environments.
Enosis added that patient enrollment is currently in progress.
“We are convinced that this partnership will help innovate the field by shifting the focus from the psychedelic substance to the psychedelic experience and its integration, supporting patients in every step of the way through their journey into well-being,” said Sergio Pérez Rosal, Co-Founder and CEO of OVID Clinics.
